05/30
Headlines

OVAS

Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Jason Knox03 mins

Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and…

Read More

Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

Colin Pettis02 mins

ArQule Inc. (NASDAQ:ARQL) announced that the Company will present at the Needham 13th Annual Healthcare Conference. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website http://www.arqule.com. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.92% in last session and finished the day at $1.66. Traded volume was…

Read More

Today’s Stocks : Acasti Pharma Inc. (NASDAQ:ACST), OvaScience, Inc. (NASDAQ:OVAS), Jack Henry & Associates Inc. (NASDAQ:JKHY), InvenSense, Inc. (NYSE:INVN), Facebook Inc (NASDAQ:FB)

Mark Doerr03 mins

On Sep 30, Acasti Pharma Inc. (NASDAQ:ACST), announces top-line results for its pharmacokinetic (PK) trial evaluating the bioavailability and safety of CaPre® on healthy individuals taking single and multiple daily oral doses of the Corporation’s new investigational drug candidate composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain…

Read More

Traders Are Watching : Twenty-First Century Fox (NASDAQ:FOXA), Cliffs Natural Resources (NYSE:CLF), EMCORE (NASDAQ:EMKR), Chimera Investment Corporation (NYSE:CIM), OvaScience (NASDAQ:OVAS)

John Meady03 mins

Twenty-First Century Fox, Inc. (NASDAQ:FOXA) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a report released on Tuesday. The firm currently has a $35.30 price objective on the stock. Zacks‘s price target suggests a potential upside of 2.50% from the stock’s previous close. Twenty-First Century Fox, Inc. (NASDAQ:FOXA) belongs to…

Read More

Stocks in Focus: Lloyds Banking Group (NYSE:LYG), ServiceNow (NYSE:NOW), Cutera (NASDAQ:CUTR), Trulia (NYSE:TRLA), OvaScience, Inc. (NASDAQ:OVAS)

Ryan Holtz02 mins

Lloyds Banking Group PLC (NYSE:LYG)‘s stock had its “buy” rating restated by research analysts at Investec in a report released on Tuesday. Lloyds Banking Group plc (NYSE:LYG) belongs to Financial sector. Its net profit margin is -4.90% and weekly performance is 2.59%. On last trading day company shares ended up $5.15. Lloyds Banking Group plc…

Read More

Hot Watch List: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Enanta Pharmaceuticals (NASDAQ:ENTA), Cheesecake Factory Incorporated (NASDAQ:CAKE), Randgold Resources Limited (NASDAQ:GOLD), OvaScience, Inc. (NASDAQ:OVAS)

Ryan Holtz03 mins

On 7 AUG OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced second quarter 2014 financial results. Revenue for the three and six months ended June 30, 2014 was $4.9 million and $16.7 million, respectively.  This compares with $6.3 million and $11.4 million, respectively, in the same periods in 2013. Revenue earned in the second quarter of 2014 consists…

Read More